ACT 2024 Annual Meeting

November 17-20, 2024 | Austin, Texas

Proud Platinum Sponsor of American College of Toxicology 

Thank you to everyone who visited with us at ACT! It was great to connect with so many industry professionals, share insights and showcase our science. If you missed the event, please access the resources below or contact us for more information.

Exhibitor-Hosted Session

Radiopharmaceuticals Drug Development for Oncology: Is my molecule a potential drug? 

Radiopharmaceutical development has been changing the face of the oncology therapeutic arsenal. This session reviewed the recent history of regulatory requirements, core elements of study design, including technical considerations required to manage the radioisotopes being deployed, investment and merger news, and provided insight into practical experiences managing these programs.

Posters

View each presented poster below:

1. Assessment of Leading Regulatory T Cell Immunophenotyping Methods using Flow Cytometry 
2. Development of an Electrochemiluminescence-Based Immunoassay to Evaluate T Cell-Dependent IgG and IgM Responses to Keyhole Limpet Hemocyanin (KLH) Administration in the Juvenile New Zealand White Rabbit
3. Comparison of intratracheal and inhaled AAV pulmonary deposition in two species
4. Mouse versus Rabbit: Time Course of Corneal Ocular Toxicity of an Antibody Drug Conjugate with a Maytansinoid Payload
5. Evaluation of Endogenous and ex vivo Stimulated Matrices for Validation of Cytokine Expression Assessment
6. Inhaled delivery of a novel broad spectrum immune modulator to minipigs produces a favorable toxicity profile
7. A 29 Day Two Dose and 3 Day One Dose Research and Development Study of Intrathecal Injection or Epidural Infusion in Rats
8. Retrospective Analysis of Nonclinical Regulatory Strategy for Approved Oncology Antibody-Drug Conjugates

With more than 80 years of toxicology experience, Labcorp is focused on delivering the answers you need to move your program to the next milestone. Our global capacity, flexible scheduling and rapid study initiation creates a streamlined approach to nonclinical services, which means successful design and execution of your program across discovery, safety pharmacology, toxicology, pathology, bioanalytical, and drug metabolism and pharmacokinetics.